Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Protein A-based S. aureus vaccine
- Development stage
- Preclinical
- Lead developer
- ImmunArtes
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intravenous, Subcutaneous
01
Overview
ImmunArtes is developing a protein-based vaccine targeting Staphylococcus aureus Protein A (SpA) for the prevention and treatment of S. aureus infections, including methicillin-resistant Staphylococcus aureus (MRSA). The vaccine utilizes a detoxified variant of Protein A, such as SpAKKAA, which has been engineered to eliminate binding to human IgG Fcγ and VH3 immunoglobulin heavy chains. By neutralizing SpA, a key virulence factor that typically allows the bacteria to evade opsonophagocytic killing by the immune system, the vaccine aims to elicit protective antibodies that facilitate immune clearance. Preclinical studies in murine models have demonstrated safety, immunogenicity, and protective efficacy against both methicillin-susceptible (MSSA) and methicillin-resistant (MRSA) strains of S. aureus.
- Other names
- Protein A-based Staphylococcus aureus vaccineSpA vaccineImmunArtes Protein A vaccine
Beyond the preview
Go deeper on Protein A-based S. aureus vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Protein A-based S. aureus vaccine.